The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis?

“…1 Thus, glucagon-like peptide-1 receptor agonists (GLP-1RA) represent an attractive therapeutic option, as they are already approved for patients with type 2 diabetes (T2DM) and obesity. 2 Moreover, trials have shown that GLP-1RAs reduce major adverse cardiovascular events in (high-risk) diabetic/obese patients, 3,4 making them preferred over other drug classes irrespective of glycaemic control. Trials in hepatology, 5,6 on the other hand, have fallen behind and phase 3 data are still awaited.…”